Frankfurt - Delayed Quote EUR

Charles River Laboratories International, Inc. (RV6.F)

131.55
+2.65
+(2.06%)
At close: June 11 at 8:19:21 AM GMT+2
Loading Chart for RV6.F
  • Previous Close 128.90
  • Open 131.55
  • Bid 130.70 x 10000
  • Ask 131.55 x 10000
  • Day's Range 131.55 - 131.55
  • 52 Week Range 87.70 - 226.90
  • Volume 189
  • Avg. Volume 23
  • Market Cap (intraday) 6.624B
  • Beta (5Y Monthly) 1.48
  • PE Ratio (TTM) --
  • EPS (TTM) -0.54
  • Earnings Date Aug 5, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

www.criver.com

18,700

Full Time Employees

December 28

Fiscal Year Ends

Recent News: RV6.F

View More

Performance Overview: RV6.F

Trailing total returns as of 6/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RV6.F
25.99%
S&P 500 (^GSPC)
2.39%

1-Year Return

RV6.F
33.76%
S&P 500 (^GSPC)
12.04%

3-Year Return

RV6.F
37.48%
S&P 500 (^GSPC)
54.38%

5-Year Return

RV6.F
13.45%
S&P 500 (^GSPC)
100.60%

Compare To: RV6.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RV6.F

View More

Valuation Measures

Annual
As of 6/10/2025
  • Market Cap

    6.49B

  • Enterprise Value

    8.90B

  • Trailing P/E

    --

  • Forward P/E

    15.24

  • PEG Ratio (5yr expected)

    0.12

  • Price/Sales (ttm)

    1.84

  • Price/Book (mrq)

    2.21

  • Enterprise Value/Revenue

    2.49

  • Enterprise Value/EBITDA

    18.31

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.49%

  • Return on Assets (ttm)

    4.26%

  • Return on Equity (ttm)

    -0.67%

  • Revenue (ttm)

    4.02B

  • Net Income Avi to Common (ttm)

    -31.56M

  • Diluted EPS (ttm)

    -0.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    229.36M

  • Total Debt/Equity (mrq)

    92.21%

  • Levered Free Cash Flow (ttm)

    625.62M

Research Analysis: RV6.F

View More

Company Insights: RV6.F

Research Reports: RV6.F

View More

People Also Watch